CNS Drug Discoveries: Parkinson's Disease Chapter published by Espicom Business Intelligence in August, 2008. This report consists of Pages: 74 and the price starts from US $ 1040.
Abstract
Espicom' s best-selling CNS Drug Discoveries: what the future holds provides a
comprehensive examination of 5 major CNS therapy areas: multiple sclerosis,
Alzheimer' s disease, Parkinson' s disease, schizophrenia and depression. The
information below and the ordering information on this page relate to the
Parkinson' s disease chapter. To find out more about the full report, click
here.
In 2007, approximately US$3.6 billion was spent on the symptomatic treatment
of Parkinson' s disease (PD). Although this neurodegenerative disease affects
approximately 1% of the population its prevalence increases with age, thus it
is likely to become more commonplace due to patient demographics and become a
greater burden to healthcare payers.
PD patients are treated with a cocktail of drugs which are adapted to the
patients' needs as the disease progresses. There is no cure and current
therapies are relatively effective at treating the symptoms in the early
stages but less so in advanced PD, and there remain significant side effects.
Whilst generic levodopa remains the cornerstone of treatment and is widely
available relatively cheaply, its chronic use is not necessarily limited by
budget, but by its long-term effectiveness. Hence, the more costly dopamine
agonists have gained utility in the treatment of the early stage of the
disease helping to spare levodopa treatment.
However, over the next six years many of the leading dopamine agonists face
patent expiration, enabling generics to become more freely available.
Meanwhile some companies have new improved dopamine agonists in their
pipelines such as Solvay' s pardoprunox or more potent monoamine oxidase
inhibitors such as Merck KGaA/Newron' s safinamide.
Some companies have picked up the gauntlet and run to develop new
disease-modifying agents which could revolutionise the way advanced PD is
treated. For example, Bayer' s high-risk, high-reward approach to developing
spheramine is a novel cell therapy that may halt the progression of PD.
Key PD questions answered include:
- What percentage of the treatable population for PD has been diagnosed in
Europe, US and Japan?
- Which PD products will face generic challenges by 2014?
- What are the commercial prospects for Bayer' s revolutionary
disease-modifying agent spheramine?
- By 2014, Boehringer Ingelheim and GSK will have lost considerable PD
market share - to whom and what products will make the difference?
Key products analysed and forecast
- Apokyn - Britannia/Ipsen
- Azilect - Lundbeck/Teva Pharmaceuticals
- Comtan franchise - Novartis/Orion
- Istradefylline - Kyowa Hakko
- Mirapex - Boehringer Ingelheim
- Neupro - UCB
- Pardoprunox - Solvay
- Requip - GlaxoSmithKline
- Safinamide - Merck KGaA/Newron
- Spheramine - Bayer/Titan Pharmaceuticals
Table of Contents
Parkinson' s Disease
THE FACTS
- What is Parkinson' s disease and why are we interested in it?
- PATIENT STATISTICS
- Incidence, diagnosis rates and treatment; now and in the future
- PATIENT MODEL
- The treated PD patient population will grow by 3.6 percent per annum
- Summary of PD Patient Population Forecasts 2007A-2014E
- Model Assumptions
- DRUG GROWTH DRIVERS
- Potential Diagnostic Biomarkers for PD
- DRUG GROWTH RISKS/DAMPENERS
THE PD MARKET
- Global CNS Market 2007 (US$91.9 billion)
- PD Global Sales Split (2006)
- The Major Players
- Market Share of PD Players by Sales (Dec 2007A)
- Players and Products in 2014
- Market Share of PD Players by Sales (Dec 2014E)
CURRENT PD TREATMENTS
- Leading Brands
- Comparison of Leading PD Drug Classes
- Current Products' Patent Exposure
- Patent Exposure of Leading PD Brands
- ANALYSIS OF LEADING BRANDS
- Dopamine Agonists
- Apokyn
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the market-place/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor ratio analysis
- Neupro
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Clinical Endpoint of Phase III trials with Neupro 1) Europe 2) the US
- Management/clinical expertise
- Competition within the market-place/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor ratio analysis
- Sifrol/Mirapex/Mirapexin
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the market-place/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor ratio analysis
- Requip
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the market-place/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor ratio analysis
- Monoamine Oxidase Inhibitors
- Azilect
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the market-place/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor ratio analysis
- Catechol-O-Methyltransferase Inhibitors
- Comtan/Comtess/Stalevo
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the market-place/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor ratio analysis
- GLOBAL SALES FORECASTS OF CURRENT TREATMENTS 2007A - 2014E
- Sales Forecasts of Current Leading PD Drugs
- Model Assumptions
NEW DRUGS IN R&D
- Drugs in Development to Treat PD
- ANALYSIS OF LATE-PHASE DRUGS
- New Drugs in Phase III Development to Treat PD
- Istradefylline
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the market-place/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor ratio analysis
- Pardoprunox
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the market-place/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor ratio analysis
- Safinamide
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the market-place/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor ratio analysis
- GLOBAL SALES FORECASTS OF LATE-PHASE PD DRUGS 2009E- 2014E
- Sales Forecasts of Late-Phase Developmental PD Drugs
- Model Assumptions
- ANALYSIS OF PHASE II DRUGS
- New Drugs in Early Clinical Development to Treat PD
- Spheramine
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the market-place/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor ratio analysis
- VR040
COMPETITOR RATIO ANALYSIS
- COMPETITOR RATIO ANALYSIS - PRODUCTS
- CR Analysis of PD Agents Approved by 2014 - Based on Drug Class
- COMPETITOR RATIO ANALYSIS - COMPANIES
- CR Analysis of PD Agents Approved by 2014 - Based on Company
- WINNERS & LOSERS
- Summary of Key Companies and Drugs in the PD Market by 2014
DISCON TINUATION OF DRUGS
- PD Drugs Discontinued from Clinical Development
PD APPENDIX 1
- Phase Transition Probability
- Probability of Launch
PD APPENDIX 2
- PD Patient Model
- Summary of PD Patient Population Forecasts
PD APPENDIX 3
- Global PD Drugs Sales 2007A-2014E
- Global PD Drug Sales 2007A-2014E
PD APPEN DIX 4
- Competitor Ratio Analysis Criteria
- Key PD Drugs on the Market by 2014
PARKINSON ' S DISEASE GLOSARY
PARKINSON ' S DISEASE REFERENCES
ACRONYMS
